Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Truell Conservation Foundation is a UK-based charitable organization and investment vehicle founded in 2005 by Edmund and Danny Truell. While its primary philanthropic missions include environmental conservation and supporting the families of the UK armed forces, the foundation is a significant actor in the life sciences sector through its role as the founder and primary backer of ViroCell Biologics. ViroCell is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the design and GMP-compliant manufacture of viral vectors for cell and gene therapies. The foundation leverages its capital and investment expertise to address critical bottlenecks in the biotechnology industry, specifically the global shortage of viral vector manufacturing capacity. By bridging the gap between charitable endowment and high-tech innovation, the Truell Conservation Foundation supports the advancement of novel treatments for cancer and rare genetic diseases.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Truell Conservation Foundation.